184 related articles for article (PubMed ID: 36941564)
1. Establishing a prognostic model of chromatin modulators and identifying potential drug candidates in renal clear cell patients.
Liu P; Luo J; Tan N; Li C; Xu J; Yang X
BMC Bioinformatics; 2023 Mar; 24(1):104. PubMed ID: 36941564
[TBL] [Abstract][Full Text] [Related]
2. Identification of molecular subtypes based on chromatin regulator and tumor microenvironment infiltration characterization in papillary renal cell carcinoma.
Tang Q; Pan D; Xu C; Chen L
J Cancer Res Clin Oncol; 2023 Jan; 149(1):231-245. PubMed ID: 36404389
[TBL] [Abstract][Full Text] [Related]
3. Construction and validation of a chromatin regulator-related gene signature for prognostic and therapeutic significance of clear cell renal cell carcinoma.
Zhang C; Zeng J; Ye C; Tian K; Xian Z
Transl Cancer Res; 2024 Jan; 13(1):150-172. PubMed ID: 38410230
[TBL] [Abstract][Full Text] [Related]
4. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
5. Identification of a chromatin regulator signature and potential candidate drugs for bladder cancer.
Zhu K; Liu X; Deng W; Wang G; Fu B
Hereditas; 2022 Feb; 159(1):13. PubMed ID: 35125116
[TBL] [Abstract][Full Text] [Related]
6. An immune-related lncRNA risk coefficient model to predict the outcomes in clear cell renal cell carcinoma.
Tang C; Qu G; Xu Y; Yang G; Wang J; Xiang M
Aging (Albany NY); 2021 Dec; 13(24):26046-26062. PubMed ID: 34954690
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma.
Lu C; Wang Y; Nie L; Chen L; Li M; Qing H; Li S; Wu S; Wang Z
Front Immunol; 2022; 13():934243. PubMed ID: 36189255
[TBL] [Abstract][Full Text] [Related]
8. A promising Prognostic risk model for advanced renal cell carcinoma (RCC) with immune-related genes.
Cao P; Wu JY; Zhang JD; Sun ZJ; Zheng X; Yu BZ; Cao HY; Zhang FL; Gao ZH; Wang W
BMC Cancer; 2022 Jun; 22(1):691. PubMed ID: 35739510
[TBL] [Abstract][Full Text] [Related]
9. Construction and Validation of a Novel Cuproptosis-Related Seven-lncRNA Signature to Predict the Outcomes, Immunotherapeutic Responses, and Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma.
Zhang H; Ning Z; Wang B; Liu Y; Tao B; Zhang G; Liu H; Wang C
Dis Markers; 2023; 2023():7219794. PubMed ID: 36741910
[TBL] [Abstract][Full Text] [Related]
10. Integrated analysis on the N6-methyladenosine-related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma.
Qiu Y; Wang X; Fan Z; Zhan S; Jiang X; Huang J
Immun Inflamm Dis; 2021 Dec; 9(4):1596-1612. PubMed ID: 34432955
[TBL] [Abstract][Full Text] [Related]
11. A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma.
Wu Z; Shen Y; Fan D; Liu J; Chen D; Wang K; Xu X
Int Immunopharmacol; 2021 Jan; 90():107119. PubMed ID: 33243605
[TBL] [Abstract][Full Text] [Related]
12. Construction and validation of an autophagy-related long noncoding RNA signature for prognosis prediction in kidney renal clear cell carcinoma patients.
Yu J; Mao W; Xu B; Chen M
Cancer Med; 2021 Apr; 10(7):2359-2369. PubMed ID: 33650306
[TBL] [Abstract][Full Text] [Related]
13. Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma.
Sun Z; Li T; Xiao C; Zou S; Zhang M; Zhang Q; Wang Z; Zhan H; Wang H
World J Surg Oncol; 2022 Apr; 20(1):120. PubMed ID: 35422048
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of MFN2 as a prognostic biomarker associated with immune cell infiltration in renal clear cell carcinoma.
Cheng L; Wang Z; Nie L; Yang C; Huang H; Lin J; Zhuo D
Int Immunopharmacol; 2022 Oct; 111():109169. PubMed ID: 36007389
[TBL] [Abstract][Full Text] [Related]
15. Predicting response of immunotherapy and targeted therapy and prognosis characteristics for renal clear cell carcinoma based on m1A methylation regulators.
Li L; Tan H; Zhou J; Hu F
Sci Rep; 2023 Aug; 13(1):12645. PubMed ID: 37542141
[TBL] [Abstract][Full Text] [Related]
16. Seven chromatin regulators as immune cell infiltration characteristics, potential diagnostic biomarkers and drugs prediction in hepatocellular carcinoma.
Chai JW; Hu XW; Zhang MM; Dong YN
Sci Rep; 2023 Oct; 13(1):18643. PubMed ID: 37903974
[TBL] [Abstract][Full Text] [Related]
17. A novel chromatin regulator-related immune checkpoint related gene prognostic signature and potential candidate drugs for endometrial cancer patients.
Liu Z; Yang H; Chen Z; Jing C
Hereditas; 2022 Oct; 159(1):40. PubMed ID: 36253800
[TBL] [Abstract][Full Text] [Related]
18. A novel risk score model based on fourteen chromatin regulators-based genes for predicting overall survival of patients with lower-grade gliomas.
Zhang Y; Yu B; Tian Y; Ren P; Lyu B; Fu L; Chen H; Li J; Gong S
Front Genet; 2022; 13():957059. PubMed ID: 36246611
[No Abstract] [Full Text] [Related]
19. Identification of a chromatin regulator signature and potential prognostic ability for adrenocortical carcinoma.
Li J; Jia Y; Tang L; Zhang R; Zhang Y
Front Genet; 2022; 13():948353. PubMed ID: 36092868
[No Abstract] [Full Text] [Related]
20. A novel 10 glycolysis-related genes signature could predict overall survival for clear cell renal cell carcinoma.
Xing Q; Zeng T; Liu S; Cheng H; Ma L; Wang Y
BMC Cancer; 2021 Apr; 21(1):381. PubMed ID: 33836688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
